The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

Cardiorenal effects of SGLT2 and incretin agents SGLT2 inhibitors work directly on the kidney through the SGLT2 cotransporter to directly improve energy metabolism and function in the kidney.

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...